The prophylactic antiviral activity of systemically administered human interferon preparations was tested in 36 rhesus monkeys against vaccinia virus injected into the skin. All nine control monkeys developed typical vaccinia skin lesions. Eight of nine monkeys treated with daily intramuscular injections of leucocyte interferon (5 × 105 units/kg) from day -1 to day +7 after vaccination were completely protected. No lesions developed after discontinuation of therapy, Administration of the same amounts of leucocyte interferon intravenously (i.v.) was equally effective. Daily intramuscular (i.m.) injections of lower doses of leucocyte interferon (1.25 × 105 units/kg; 0.5 × 105 units/kg) decreased the severity of the skin lesions. Lesion scores correlated inversely with the dose of interferon. Four of six animals receiving daily i.m. injections of fibroblast interferon (5 × 105 units/kg) and one of three animals treated i.v. with the same dose were protected against vaccinia virus, and the lesions in the other monkeys were smaller. Intramuscular injections of 5 × 105 units/kg of fibroblast interferon or 1.25 × 105 units/kg of leucocyte interferon resulted in comparable serum levels and had comparable efficacy in reducing lesion scores.
ArvinA. M.,
FeldmanS.,
MeriganT. C.1978; Human leukocyte interferon in the treatment of varicella in children with cancer: a preliminary controlled trial. Antimicrobial Agents and Chemotherapy 13:605–607
BilliauA.,
Van DammeJ.,
Van LeuvenF.,
EdyV. G.,
De leyM.,
CassimanJ.-J.,
Van Den BergheH,
de somerP.1979; Human fibroblast interferon for clinical trials: production, partial purification and characterization. Antimicrobial Agents and Chemotherapy 16:49–55
CantellK.,
HirvonenS.,
MogensenK. E.,
PyhalaL.1974; Human leukocyte interferon: production, purification, stability, and animal experiments. In In Vitro, Proceedings of a Tissue Culture Association Workshop, 1973 pp 35–38 Edited by
WaymouthC.
Rockville, Md.: Tissue Culture Association;
CheesemanS. H.,
RubinR. H.,
StewartJ. A.,
Tolkoff-RubinN. E.,
CosimiA. B.,
CantellK.,
GilbertJ.,
WinkleS.,
HerrinJ. T.,
BlackP. H.,
RussellP. S.,
HirschM. S.1979; Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. New England Journal of Medicine 300:1345–1349
EdyV. O.,
BilliauA.,
De SomerP.1976; Human fibroblast and leucocyte interferons show different dose-response curves in assay of cell protection. Journal of General Virology 31:251–255
FinterN. B.1969; Dye uptake methods for assessing viral cytopathogenicity and their application to interferon assays. Journal of General Virology 5:419–427
HekkerA. C.,
BosJ. M.,
SmithL.1973; A stable freeze-dried smallpox vaccine made in monolayer cultures of primary rabbit kidney cells. Journal of Biological Standardization 1:21–32
MeriganT. C.,
RandK. H.,
PollardR. B.,
AbdallahP. S.,
JordanG. W.,
FriedR. P.1978; Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. New England Journal of Medicine 298:981–987
PintoC. A.,
HaffR. F.,
ValentaJ. R.,
PaganoJ. F.,
DicuolloC. J.,
FerlautoR. J.1969; Human interferon. II. Biological activity. In Symposia Series in Immunobiological Standardization vol 14 pp 105–112 Basel: S. Karger;
SundmacherR.,
CantellK.,
SkodaR.,
HallermannC.,
Neumann-HaefelinD.1978; Human leukocyte and fibroblast interferon in a combination therapy of dendritic keratitis. Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie 208:229–233
WeimarW.,
SchellekensH.,
LameijerL. D. F.,
MasurelN.,
EdyV. G.,
BilliauA.,
De SomerP.1978; Double-blind study of interferon administration in renal transplant recipients. European Journal of Clinical Investigation 8:255–258
WeimarW.,
HeijtinkR. A.,
SchalmS. W.,
SchellekensH.1979; Differential effects of fibroblast and leucocyte interferon in HBsAg positive chronic active hepatitis. European Journal of Clinical Investigation 9:151–154